Franck Morin

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio et al. · The Lancet · 2016 · 984 citations

Medicine, Molecular Medicine, Oncology +11

Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial

Gérard Zalcman, Julien Mazières, J. Margery et al. · The Lancet · 2015 · 972 citations

Medicine, Oncology, Pharmacology +10

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Arnaud Scherpereel, Julien Mazières, Laurent Greillier et al. · The Lancet Oncology · 2019 · 458 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network

Michèle Beau‐Faller, Nathalie Prim, Anne-Marie Ruppert et al. · Annals of Oncology · 2013 · 320 citations · Full text

Medicine, Genetics, Oncology +7

COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Jérôme Avouac, Élodie Drumez, É. Hachulla et al. · The Lancet Rheumatology · 2021 · 291 citations · Full text

Life Sciences, Immunology, Internal Medicine +14